Form D · Biotechnology
Mekonos, Inc.
San Francisco, CA · CIK 0001838228
Offering snapshot reported Nov 9, 2021 · SEC filing
- Reported sold
- $25M Offering amount: $25M
- Investors reported
- 23 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 14, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 9, 2021 | Initial | $24,979,834 | No comparison | 23 | SEC filing |
| Dec 31, 2020 | Initial | $4,506,357 | No comparison | 16 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-420432
Series A Preferred Stock; Common Stock issuable upon conversion
Source: Form D, filed Nov 9, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Kurt Keilhacker | Director |
| Anil Narasimha | Director, Executive |
| Gregory Sitters | Executive |
| Neil Tiwari | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
44 Montgomery Street, Suite 300
San Francisco, CA, 94104
San Francisco, CA, 94104